摘要
肾癌是泌尿外科常见的恶性肿瘤,其发病机制复杂,临床无明显症状,多数肾癌患者检查时已确诊为晚期。转移性肾癌(mRCC)占初诊肾癌的20%~30%,放疗及化疗效果不佳,故其预后差,转移患者的5年生存率不足10%。目前,mRCC的主要非手术治疗手段包括细胞因子及靶向药物治疗,另外免疫治疗也成为mRCC的研究热点。本文就mRCC治疗的现状及进展作一综述,包括靶向药物治疗,如受体络氨酸激酶抑制剂及mTOR抑制剂;新兴的免疫治疗,如PD-1/PD-L1的免疫抑制剂。
Renal cancer is a common malignant tumor in urology,with complicated pathogenesis and no obvious clinical symptoms.Metastatic renal cancer accounts for 20%-30%of the newly diagnosed renal cancer.The 5-year survival rate for metastatic patients is less than 10%.At present,the main non-surgical treatment means of mRCC include cytokines and targeted drug therapy,and immunotherapy has also become a research hotspot of mRCC.The current status and research progress of mRCC therapy were reviewed.The medical treatment methods of metastatic renal cancer,such as receptor tyrosine kinase inhibitors and mTOR inhibitors;immunotherapies,such as immunosuppressants for PD-1/PD-L1 were also discussed.
作者
熊斌
鲁伟
Xiong Bin;Lu Wei(Department of Urology,Nanchuan Hospital,the First Affiliated Hospital of Chongqing Medical University,Chongqing 408400,China)
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
2021年第4期308-311,共4页
Chinese Journal of Urology
关键词
癌
肾细胞
转移性肾细胞癌
靶向治疗
免疫疗法
Carcinoma,Renal cell
Metastatic renal cell carcinoma
Targeted therapy
Immunotherapy
